Cetera Investment Advisers Has $598,000 Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Cetera Investment Advisers lessened its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,861 shares of the biotechnology company’s stock after selling 241 shares during the quarter. Cetera Investment Advisers’ holdings in Blueprint Medicines were worth $598,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at about $51,000. Headlands Technologies LLC bought a new stake in Blueprint Medicines during the 4th quarter valued at approximately $65,000. Thematics Asset Management bought a new stake in Blueprint Medicines during the 4th quarter valued at approximately $72,000. Covestor Ltd grew its holdings in Blueprint Medicines by 62.7% in the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 375 shares during the last quarter. Finally, Asset Management One Co. Ltd. bought a new position in Blueprint Medicines in the 4th quarter worth approximately $88,000.

Insider Buying and Selling at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. This trade represents a 3.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 2,752 shares of the company’s stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $103.13, for a total transaction of $283,813.76. Following the sale, the insider now directly owns 16,944 shares in the company, valued at $1,747,434.72. This represents a 13.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,777 shares of company stock valued at $1,256,490. 4.21% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group started coverage on Blueprint Medicines in a research report on Monday, March 17th. They issued a “buy” rating and a $135.00 price objective for the company. Needham & Company LLC cut their target price on shares of Blueprint Medicines from $133.00 to $130.00 and set a “buy” rating for the company in a research note on Monday, April 28th. JMP Securities restated a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Morgan Stanley started coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines has a consensus rating of “Moderate Buy” and a consensus price target of $126.56.

Blueprint Medicines Stock Up 1.2%

Shares of BPMC opened at $101.50 on Tuesday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a 50-day moving average price of $90.99 and a two-hundred day moving average price of $94.58. The stock has a market cap of $6.56 billion, a price-to-earnings ratio of -93.98 and a beta of 0.83. Blueprint Medicines Co. has a 12 month low of $73.04 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The company had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Blueprint Medicines’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.40 EPS. Equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.